Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

11.90 +0.03 (+0.25%)
Streaming Delayed Price Updated: 12:27 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears ↗
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved... 
Via MarketBeat
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Thomas Englese to Chief Commercial Officer
Via Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Cantor 2026 Global Healthcare Conference
Via Investor Brand Network
News headline image
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline ↗
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major... 
Via MarketBeat
Tonix Pharmaceuticals (NASDAQ:TNXP) Beats Revenue Estimates in First Full Quarter of TONMYA Sales ↗
Via Chartmill
News headline image
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript ↗
TONMYA sales hit $11 million in its second quarter on market. 
Via The Motley Fool
Topics Earnings
News headline image
Tonix Pharmaceuticals Q2 Earnings Call Highlights ↗
Tonix Pharmaceuticals (NASDAQ:TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said... 
Via MarketBeat
Topics Earnings
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
Via Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in August, September Investor Conferences
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives FDA Feedback for Lyme Disease Prevention Study
Via Investor Brand Network
MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Schedules Second-Quarter 2026 Results Call for Aug. 10
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Mpox Research Supporting TNX-801 Vaccine Development
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives
Via Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Enrolls First Patient in Phase 2 Depression Trial
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in BTIG Infectious Disease Day 2026
Via Investor Brand Network
MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Coverage to 52 Million Commercial Lives
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Data Highlighting Widespread Opioid Use Among Fibromyalgia Patients
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Phase 1 TNX-1500 Data Supporting Advancement into Phase 2
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Fibromyalgia Burden Data at ISPOR 2026
Via Investor Brand Network
TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Fibromyalgia Real-World Data at ISPOR 2026
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Two May Investor Conferences
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures GPO Agreement Covering 35 Million Lives for TONMYA
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data and Plans Phase 2 Study for Lyme Disease Prevention Candidate
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Publication of TONMYA Pharmacokinetic Study in Peer-Reviewed Journal
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data for Lyme Disease Candidate TNX-4800, Plans Phase 2 Study
Via Investor Brand Network
News headline image
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? ↗
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from late... 
Via Benzinga
Topics Regulatory Compliance
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4 and Full-Year 2025 Results, Highlights Launch of TONMYA(TM)
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.